Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Felbamate
Drug ID BADD_D00871
Description Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Indications and Usage For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Marketing Status Prescription
ATC Code N03AX10
DrugBank ID DB00949
KEGG ID D00536
MeSH ID D000078328
PubChem ID 3331
TTD Drug ID D05KON
NDC Product Code 51525-0442; 51672-4185; 63629-1944; 0037-0431; 62559-731; 17381-554; 0037-0430; 65162-734; 43826-255; 47621-054; 42385-721; 51672-4172; 69988-0032; 51672-4186; 72578-056; 66689-825; 51525-0430; 46016-2542; 62559-730; 16714-775; 73223-003; 47781-630; 47781-627; 70771-1077; 63629-1937; 43826-256; 0121-0891; 72578-057; 65162-686; 0037-0442; 70771-1078; 51525-0431; 65162-735; 22365-007
Synonyms Felbamate | 2-Phenyl-1,3-propanediol dicarbamate | 2 Phenyl 1,3 propanediol dicarbamate | Taloxa | Felbatol | Felbamyl | ADD-03055 | ADD 03055 | ADD03055 | (3-Carbamoyloxy-2-phenyl-propyl) carbamate | W-554 | W 554 | W554
Chemical Information
Molecular Formula C11H14N2O4
CAS Registry Number 25451-15-4
SMILES C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityCytochrome P450 3A4P08684T378489606477; 9314612
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight increased13.15.01.006--
Hypoacusis04.02.01.006--
Brain oedema17.07.02.003; 12.01.10.010--
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Affect lability19.04.01.001--Not Available
Foetal death08.04.01.011; 18.01.02.003--
Haemorrhage24.07.01.002--Not Available
Haemorrhage urinary tract24.07.01.007; 20.02.03.005--Not Available
Stomach dilation procedure25.02.03.001--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Antinuclear antibody positive13.06.01.003--Not Available
Neurological symptom17.02.05.010--Not Available
Foetal disorder18.03.02.001--Not Available
Lymphoproliferative disorder16.21.02.001; 01.13.02.001--Not Available
Mental disorder19.07.01.002--Not Available
Peripheral embolism24.01.02.005--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Renal impairment20.01.03.010--Not Available
Congenital genital malformation21.15.02.001; 03.03.02.002--Not Available
X-linked lymphoproliferative syndrome11.05.10.005; 10.03.01.003; 03.17.01.002; 01.13.02.003; 16.21.02.003--Not Available
Acute kidney injury20.01.03.016--
The 8th Page    First    Pre   8    Total 8 Pages